{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:10:05Z","timestamp":1792613405673,"version":"4.5.0"},"update-to":[{"DOI":"10.1371\/journal.pmed.1004401","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000}}],"reference-count":94,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["T32 AI007433"],"award-info":[{"award-number":["T32 AI007433"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI146555"],"award-info":[{"award-number":["R01 AI146555"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI146555"],"award-info":[{"award-number":["R01 AI146555"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Background<\/jats:title><jats:p>Emerging evidence suggests that shortened, simplified treatment regimens for rifampicin-resistant tuberculosis (RR-TB) can achieve comparable end-of-treatment (EOT) outcomes to longer regimens. We compared a 6-month regimen containing bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) to a standard of care strategy using a 9- or 18-month regimen depending on whether fluoroquinolone resistance (FQ-R) was detected on drug susceptibility testing (DST).<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methods and findings<\/jats:title><jats:p>The primary objective was to determine whether 6 months of BPaLM is a cost-effective treatment strategy for RR-TB. We used genomic and demographic data to parameterize a mathematical model estimating long-term health outcomes measured in quality-adjusted life years (QALYs) and lifetime costs in 2022 USD ($) for each treatment strategy for patients 15 years and older diagnosed with pulmonary RR-TB in Moldova, a country with a high burden of TB drug resistance. For each individual, we simulated the natural history of TB and associated treatment outcomes, as well as the process of acquiring resistance to each of 12 anti-TB drugs. Compared to the standard of care, 6 months of BPaLM was cost-effective. This strategy was estimated to reduce lifetime costs by $3,366 (95% UI: [1,465, 5,742]<jats:italic>p<\/jats:italic>&lt; 0.001) per individual, with a nonsignificant change in QALYs (\u22120.06; 95% UI: [\u22120.49, 0.03]<jats:italic>p<\/jats:italic>= 0.790). For those stopping moxifloxacin under the BPaLM regimen, continuing with BPaL plus clofazimine (BPaLC) provided more QALYs at lower cost than continuing with BPaL alone. Strategies based on 6 months of BPaLM had at least a 93% chance of being cost-effective, so long as BPaLC was continued in the event of stopping moxifloxacin. BPaLM for 6 months also reduced the average time spent with TB resistant to amikacin, bedaquiline, clofazimine, cycloserine, moxifloxacin, and pyrazinamide, while it increased the average time spent with TB resistant to delamanid and pretomanid. Sensitivity analyses showed 6 months of BPaLM to be cost-effective across a broad range of values for the relative effectiveness of BPaLM, and the proportion of the cohort with FQ-R. Compared to the standard of care, 6 months of BPaLM would be expected to save Moldova\u2019s national TB program budget $7.1 million (95% UI: [1.3 million, 15.4 million]<jats:italic>p<\/jats:italic>= 0.002) over the 5-year period from implementation. Our analysis did not account for all possible interactions between specific drugs with regard to treatment outcomes, resistance acquisition, or the consequences of specific types of severe adverse events, nor did we model how the intervention may affect TB transmission dynamics.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Conclusions<\/jats:title><jats:p>Compared to standard of care, longer regimens, the implementation of the 6-month BPaLM regimen could improve the cost-effectiveness of care for individuals diagnosed with RR-TB, particularly in settings with a high burden of drug-resistant TB. Further research may be warranted to explore the impact and cost-effectiveness of shorter RR-TB regimens across settings with varied drug-resistant TB burdens and national income levels.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pmed.1004401","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T17:29:19Z","timestamp":1714757359000},"page":"e1004401","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8933-2188","authenticated-orcid":true,"given":"Lyndon P.","family":"James","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9488-2571","authenticated-orcid":true,"given":"Fayette","family":"Klaassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4233-9080","authenticated-orcid":true,"given":"Sedona","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0825-7199","authenticated-orcid":true,"given":"Jennifer","family":"Furin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4890-5728","authenticated-orcid":true,"given":"Molly F.","family":"Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9276-5750","authenticated-orcid":true,"given":"Reza","family":"Yaesoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dumitru","family":"Chesov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1032-0617","authenticated-orcid":true,"given":"Nelly","family":"Ciobanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7331-8138","authenticated-orcid":true,"given":"Alexandru","family":"Codreanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5059-8002","authenticated-orcid":true,"given":"Valeriu","family":"Crudu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8091-7198","authenticated-orcid":true,"given":"Ted","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2571-016X","authenticated-orcid":true,"given":"Nicolas A.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"key":"pmed.1004401.ref001","unstructured":"WHO consolidated guidelines on tuberculosis. Module 4: treatment \u2010 drug-resistant tuberculosis treatment, 2022 update. [date accessed: 2023 Mar 29]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240063129."},{"key":"pmed.1004401.ref002","unstructured":"WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment \u2010 Drug-Resistant Tuberculosis Treatment. World Health Organization. 2020. Available from: https:\/\/www.who.int\/publications-detail-redirect\/9789240007048."},{"key":"pmed.1004401.ref003","doi-asserted-by":"crossref","first-page":"1901467","DOI":"10.1183\/13993003.01467-2019","article-title":"Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis","volume":"55","author":"S Abidi","year":"2020","journal-title":"Eur Respir J"},{"key":"pmed.1004401.ref004","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1093\/cid\/ciz1107","article-title":"Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens","volume":"71","author":"RR Kempker","year":"2019","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"pmed.1004401.ref005","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline\u2013Pretomanid\u2013Linezolid Regimens for Drug-Resistant Tuberculosis","volume":"387","author":"F Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"pmed.1004401.ref006","first-page":"893","article-title":"Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis","volume":"382","author":"F Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"pmed.1004401.ref007","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-019-4429-x","article-title":"Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations","volume":"19","author":"EA Kendall","year":"2019","journal-title":"BMC Infect Dis"},{"key":"pmed.1004401.ref008","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis","volume":"387","author":"BT Nyang\u2019wa","year":"2022","journal-title":"N Engl J Med"},{"key":"pmed.1004401.ref009","article-title":"Nine-month, all-oral regimens for rifampin-resistant tuberculosis","author":"L Guglielmetti","year":"2024","journal-title":"Infect Dis (except HIV\/AIDS)"},{"key":"pmed.1004401.ref010","unstructured":"Mitnick CD. endTB trial: Design and baseline characteristics of participants in a study of five all-oral, shortened regimens for MDR\/RR-TB. TBUnion. 2023 Nov 15; Paris. Available from: https:\/\/documents.theunion.org\/web-uploads\/UNION2023_Abstracts_High.pdf?_gl=1*1kgeq4f*_ga_8PZRTR8JPW*MTcwNTkzOTczMC4xLjAuMTcwNTkzOTczNC4wLjAuMA."},{"key":"pmed.1004401.ref011","unstructured":"Khan U. endTB trial: Efficacy results in a study of five all-oral, shortened regimens for MDR\/RR-TB. TBUnion. 2023 Nov 15; Paris. Available from: https:\/\/documents.theunion.org\/web-uploads\/UNION2023_Abstracts_High.pdf?_gl=1*1kgeq4f*_ga_8PZRTR8JPW*MTcwNTkzOTczMC4xLjAuMTcwNTkzOTczNC4wLjAuMA."},{"key":"pmed.1004401.ref012","unstructured":"Guglielmetti L. endTB trial: Safety results in a study of five shortened, all-oral regimens for MDR\/RR-TB. TBUnion. 2023 Nov 15; Paris. Available from: https:\/\/documents.theunion.org\/web-uploads\/UNION2023_Abstracts_High.pdf?_gl=1*1kgeq4f*_ga_8PZRTR8JPW*MTcwNTkzOTczMC4xLjAuMTcwNTkzOTczNC4wLjAuMA."},{"key":"pmed.1004401.ref013","unstructured":"Vel\u00e1squez G. endTB trial sub-studies: Evidence on resistance and pharmacokinetics\/ pharmacodynamics to inform practice. TBUnion. 2023 Nov 15; Paris. Available from: https:\/\/documents.theunion.org\/web-uploads\/UNION2023_Abstracts_High.pdf?_gl=1*1kgeq4f*_ga_8PZRTR8JPW*MTcwNTkzOTczMC4xLjAuMTcwNTkzOTczNC4wLjAuMA."},{"key":"pmed.1004401.ref014","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","article-title":"Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"8","author":"Z Lan","year":"2020","journal-title":"Lancet Respir Med"},{"key":"pmed.1004401.ref015","doi-asserted-by":"crossref","first-page":"e0147397","DOI":"10.1371\/journal.pone.0147397","article-title":"Psycho-Socio-Economic Issues Challenging Multidrug Resistant Tuberculosis Patients: A Systematic Review","volume":"11","author":"BE Thomas","year":"2016","journal-title":"PLoS ONE"},{"key":"pmed.1004401.ref016","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/tmi.12146","article-title":"I cry every day\u201d: experiences of patients co-infected with HIV and multidrug-resistant tuberculosis","volume":"18","author":"P Isaakidis","year":"2013","journal-title":"Trop Med Int Health TM IH"},{"key":"pmed.1004401.ref017","doi-asserted-by":"crossref","first-page":"954","DOI":"10.5588\/ijtld.12.0480","article-title":"Social, economic, and psychological impacts of MDR-TB treatment in Tijuana, Mexico: a patient\u2019s perspective","volume":"17","author":"MD Morris","year":"2013","journal-title":"Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis"},{"key":"pmed.1004401.ref018","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1590\/S1020-49892013000500004","article-title":"Tuberculosis patients in the Dominican Republic face severe direct and indirect costs and need social protection","volume":"33","author":"V Mauch","year":"2013","journal-title":"Rev Panam Salud Publica Pan Am J Public Health"},{"key":"pmed.1004401.ref019","doi-asserted-by":"crossref","first-page":"e83480","DOI":"10.1371\/journal.pone.0083480","article-title":"Alcohol, hospital discharge, and socioeconomic risk factors for default from multidrug resistant tuberculosis treatment in rural South Africa: a retrospective cohort study","volume":"8","author":"EA Kendall","year":"2013","journal-title":"PLoS ONE"},{"key":"pmed.1004401.ref020","unstructured":"Global Drug Facility (GDF) Medicines Catalog. Stop TB Partnership. 2022. Available from: https:\/\/www.stoptb.org\/sites\/default\/files\/gdfmedicinescatalog_1.pdf."},{"key":"pmed.1004401.ref021","unstructured":"Price reduction paves the way for expanded access to highly effective multidrug-resistant tuberculosis treatment. In: TB Alliance [Internet]. [date accessed: 2023 Jun 17]. Available from: https:\/\/www.tballiance.org.za\/news\/price-reduction-paves-the-way-for-expanded-access-to-highly-effective-multidrug-resistant-tuberculosis-treatment."},{"key":"pmed.1004401.ref022","doi-asserted-by":"crossref","first-page":"e02919","DOI":"10.1128\/JCM.02919-20","article-title":"Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates","volume":"60","author":"K Kaniga","year":"2022","journal-title":"J Clin Microbiol"},{"key":"pmed.1004401.ref023","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S2213-2600(18)30097-3","article-title":"Pan-tuberculosis regimens: an argument against","volume":"6","author":"K Dheda","year":"2018","journal-title":"Lancet Respir Med"},{"key":"pmed.1004401.ref024","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1473-3099(10)70264-4","article-title":"Population biological principles of drug-resistance evolution in infectious diseases","volume":"11","author":"PA zur Wiesch","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"23","key":"pmed.1004401.ref025","first-page":"S1201","article-title":"Update of drug-resistant tuberculosis treatment guidelines: A turning point","author":"E Vanino","year":"2023","journal-title":"Int J Infect Dis IJID Off Publ Int Soc Infect Dis"},{"key":"pmed.1004401.ref026","unstructured":"Practical manual on tuberculosis laboratory strengthening. 2022 update. [date accessed: 2023 Nov 21]. Available from: https:\/\/www.who.int\/publications-detail-redirect\/9789240061507."},{"key":"pmed.1004401.ref027","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.5588\/ijtld.12.0391","article-title":"New tuberculosis technologies: challenges for retooling and scale-up [State of the art series. New tools. Number 4 in the series]","volume":"16","author":"M Pai","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"pmed.1004401.ref028","doi-asserted-by":"crossref","first-page":"e0001337","DOI":"10.1371\/journal.pgph.0001337","article-title":"Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis","volume":"2","author":"S Sweeney","year":"2022","journal-title":"PLoS Glob Public Health"},{"key":"pmed.1004401.ref029","unstructured":"Global tuberculosis report 2020. [date accessed: 2023 Apr 4]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240013131."},{"key":"pmed.1004401.ref030","first-page":"2021","author":"C Yang","year":"2021","journal-title":"Phylogeography and transmission of M. tuberculosis in Moldova"},{"key":"pmed.1004401.ref031","unstructured":"Download: The New Profile of Drug-Resistant Tuberculosis in Russia: A Global and Local Perspective: Summary of a Joint Workshop by the Institute of Medicine and the Russian Academy of Medical Science | The National Academies Press. [date accessed: 2023 Nov 21]. Available from: https:\/\/nap.nationalacademies.org\/download\/13033."},{"key":"pmed.1004401.ref032","doi-asserted-by":"crossref","first-page":"13280","DOI":"10.1073\/pnas.0801200105","article-title":"Mass incarceration can explain population increases in TB and multidrug-resistant TB in European and central Asian countries","volume":"105","author":"D Stuckler","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pmed.1004401.ref033","doi-asserted-by":"crossref","first-page":"e1003933","DOI":"10.1371\/journal.pmed.1003933","article-title":"Phylogeography and transmission of M. tuberculosis in Moldova: A prospective genomic analysis","volume":"19","author":"C Yang","year":"2022","journal-title":"PLoS Med"},{"key":"pmed.1004401.ref034","unstructured":"WHO consolidated guidelines on tuberculosis. Module 4: treatment \u2010 drug-resistant tuberculosis treatment. 2022 update. [date accessed: 2023 Mar 2]. Available from: https:\/\/www.who.int\/publications-detail-redirect\/9789240063129."},{"key":"pmed.1004401.ref035","unstructured":"ID 736718 \u2010 BioProject \u2010 NCBI. [date accessed: 2023 Feb 9]. Available from: https:\/\/www-ncbi-nlm-nih-gov.ezp-prod1.hul.harvard.edu\/bioproject\/PRJNA736718."},{"key":"pmed.1004401.ref036","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s11136-014-0858-6","article-title":"The impact of tuberculosis on health utility: a longitudinal cohort study","volume":"24","author":"M Bauer","year":"2015","journal-title":"Qual Life Res"},{"key":"pmed.1004401.ref037","author":"R Ragonnet","journal-title":"Revisiting the Natural History of Pulmonary Tuberculosis: A Bayesian Estimation of Natural Recovery and Mortality Rates"},{"key":"pmed.1004401.ref038","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1473-3099(19)30309-3","article-title":"Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis","volume":"19","author":"K Romanowski","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"pmed.1004401.ref039","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00803-2016","article-title":"An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis","volume":"49","author":"ML Bastos","year":"2017","journal-title":"Eur Respir J"},{"key":"pmed.1004401.ref040","doi-asserted-by":"crossref","first-page":"e1001932","DOI":"10.1371\/journal.pmed.1001932","article-title":"Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study","volume":"12","author":"CM Yuen","year":"2015","journal-title":"PLoS Med"},{"key":"pmed.1004401.ref041","doi-asserted-by":"crossref","first-page":"123","DOI":"10.7326\/0003-4819-149-2-200807150-00008","article-title":"Initial Drug Resistance and Tuberculosis Treatment Outcomes: Systematic Review and Meta-analysis","volume":"149","author":"W Lew","year":"2008","journal-title":"Ann Intern Med"},{"key":"pmed.1004401.ref042","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00592-018-1244-6","article-title":"Evaluation of health utility values for diabetic complications, treatment regimens, glycemic control and other subjective symptoms in diabetic patients using the EQ-5D-5L","volume":"56","author":"M Takahara","year":"2019","journal-title":"Acta Diabetol"},{"key":"pmed.1004401.ref043","volume-title":"Decision making in health and medicine:integrating evidence and values","author":"University Press","year":"2014","edition":"2"},{"key":"pmed.1004401.ref044","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1056\/NEJM197703312961304","article-title":"Foundations of Cost-Effectiveness Analysis for Health and Medical Practices","volume":"296","author":"MC Weinstein","year":"1977","journal-title":"N Engl J Med"},{"key":"pmed.1004401.ref045","doi-asserted-by":"crossref","first-page":"e1640","DOI":"10.1016\/S2214-109X(23)00369-8","article-title":"Costs incurred by people receiving tuberculosis treatment in low-income and middle-income countries: a meta-regression analysis","volume":"11","author":"A Portnoy","year":"2023","journal-title":"Lancet Glob Health"},{"key":"pmed.1004401.ref046","first-page":"0","volume-title":"Theoretical Foundations of Cost-Effectiveness Analysis in Health and Medicine","author":"Cost-Effectiveness in Health and Medicine","year":"2016"},{"key":"pmed.1004401.ref047","doi-asserted-by":"crossref","first-page":"e000964","DOI":"10.1136\/bmjgh-2018-000964","article-title":"Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data","volume":"3","author":"J Ochalek","year":"2018","journal-title":"BMJ Glob Health"},{"key":"pmed.1004401.ref048","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40273-020-00915-5","article-title":"Why it\u2019s Time to Abandon the ICER","volume":"38","author":"M. Paulden","year":"2020","journal-title":"PharmacoEconomics"},{"key":"pmed.1004401.ref049","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force","volume":"25","author":"D Husereau","year":"2022","journal-title":"Value Health"},{"key":"pmed.1004401.ref050","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","article-title":"Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20146","volume":"15","author":"AH Briggs","year":"2012","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"pmed.1004401.ref051","unstructured":"TreeAge Pro Healthcare 2023. TreeAge Software, Williamstown, MA; Available from: http:\/\/www.treeage.com."},{"key":"pmed.1004401.ref052","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria; 2022. Available from: https:\/\/www.R-project.org\/."},{"key":"pmed.1004401.ref053","author":"GR Warnes","year":"2022","journal-title":"gdata: Various R Programming Tools for Data Manipulation"},{"key":"pmed.1004401.ref054","unstructured":"Wickham H, RStudio. tidyverse: Easily Install and Load the \u201cTidyverse.\u201d 2023. Available from: https:\/\/cran.r-project.org\/web\/packages\/tidyverse\/index.html."},{"key":"pmed.1004401.ref055","unstructured":"Wickham H, RStudio. stringr: Simple, Consistent Wrappers for Common String Operations. 2022. Available from: https:\/\/cran.r-project.org\/web\/packages\/stringr\/index.html."},{"key":"pmed.1004401.ref056","unstructured":"Robinson D, Hayes A, Couch [aut S, cre], Software P, PBC, et al. broom: Convert Statistical Objects into Tidy Tibbles. 2023. Available from: https:\/\/cran.r-project.org\/web\/packages\/broom\/index.html."},{"key":"pmed.1004401.ref057","author":"H Wickham","year":"2023","journal-title":"A Grammar of Data Manipulation"},{"key":"pmed.1004401.ref058","unstructured":"Kassambara A. ggpubr: \u201cggplot2\u201d Based Publication Ready Plots. 2023. Available from: https:\/\/cran.r-project.org\/web\/packages\/ggpubr\/index.html."},{"key":"pmed.1004401.ref059","author":"S Garnier","year":"2021","journal-title":"Colorblind-Friendly Color Maps for R"},{"key":"pmed.1004401.ref060","author":"S Firke","year":"2023","journal-title":"Simple Tools for Examining and Cleaning Dirty Data"},{"key":"pmed.1004401.ref061","unstructured":"Wickham H. reshape2: Flexibly Reshape Data: A Reboot of the Reshape Package. 2020. Available from: https:\/\/cran.r-project.org\/web\/packages\/reshape2\/index.html."},{"key":"pmed.1004401.ref062","unstructured":"James LP. lyndonpjames\/BPaLM_Moldova. [date accessed: 2024 Jan 22]. Available from: https:\/\/github.com\/lyndonpjames\/BPaLM_Moldova\/tree\/main."},{"key":"pmed.1004401.ref063","doi-asserted-by":"crossref","unstructured":"The CRyPTIC Consortium. A data compendium associating the genomes of 12,289 Mycobacterium tuberculosis isolates with quantitative resistance phenotypes to 13 antibiotics. Ladner J, editor. PLoS Biol. 2022;20: e3001721. doi: 10.1371\/journal.pbio.3001721","DOI":"10.1371\/journal.pbio.3001721"},{"key":"pmed.1004401.ref064","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S2213-2600(15)00036-3","article-title":"Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies","volume":"3","author":"EV Kurbatova","year":"2015","journal-title":"Lancet Respir Med"},{"key":"pmed.1004401.ref065","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003815","article-title":"Modeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis","volume":"4","author":"R Sergeev","year":"2012","journal-title":"Sci Transl Med"},{"key":"pmed.1004401.ref066","unstructured":"World Bank Open Data. Available from: https:\/\/data.worldbank.org\/."},{"key":"pmed.1004401.ref067","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S2213-2600(18)30096-1","article-title":"Pan-tuberculosis regimens: an argument for","volume":"6","author":"RS Wallis","year":"2018","journal-title":"Lancet Respir Med"},{"key":"pmed.1004401.ref068","unstructured":"Global Tuberculosis Programme. Tuberculosis Data. 2023. Available from: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/data."},{"key":"pmed.1004401.ref069","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1128\/AAC.03822-14","article-title":"Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis","volume":"59","author":"R Tasneen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"pmed.1004401.ref070","first-page":"392","article-title":"Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis","volume":"102","author":"Y Liu","year":"2021","journal-title":"Int J Infect Dis IJID Off Publ Int Soc Infect Dis"},{"key":"pmed.1004401.ref071","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4103\/ijmr.IJMR_1168_19","article-title":"Linezolid resistance in Mycobacterium tuberculosis isolates at a tertiary care centre in Mumbai","volume":"154","author":"R Nambiar","year":"2021","journal-title":"India Indian J Med Res"},{"key":"pmed.1004401.ref072","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for treatment of chronic extensively drug-resistant tuberculosis","volume":"367","author":"M Lee","year":"2012","journal-title":"N Engl J Med"},{"key":"pmed.1004401.ref073","doi-asserted-by":"crossref","unstructured":"Kohli-Lynch CN. Probabilistic sensitivity analysis and value of information analysis. 1st ed. In: Bishai D, Brenzel L, Padula W, editors. Handbook of Applied Health Economics in Vaccines. 1st ed. Oxford University PressOxford; 2023. p. 290\u2013309. doi: 10.1093\/oso\/9780192896087.003.0024","DOI":"10.1093\/oso\/9780192896087.003.0024"},{"key":"pmed.1004401.ref074","first-page":"167","volume-title":"Cost-effectiveness in Health and Medicine","author":"Valuing Health Outcomes","year":"2016","edition":"2"},{"key":"pmed.1004401.ref075","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1111\/j.1524-4733.2009.00515.x","article-title":"QALYs: The Basics","volume":"12","author":"MC Weinstein","year":"2009","journal-title":"Value Health"},{"key":"pmed.1004401.ref076","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.5588\/ijtld.12.0037","article-title":"Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis","volume":"16","author":"K Bl\u00f6ndal","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"pmed.1004401.ref077","unstructured":"World Population Prospects. UN Population Division, Department of Economic and Social Affairs. 2019. Available from: https:\/\/population.un.org\/wpp\/Download\/Files\/1_Indicators%20(Standard)\/EXCEL_FILES\/3_Mortality\/WPP2019_MORT_F15_1_LIFE_TABLE_SURVIVORS_BOTH_SEXES.xlsx."},{"key":"pmed.1004401.ref078","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00353-2018","article-title":"Analysis of loss to follow-up in 4099 multidrug-resistant pulmonary tuberculosis patients","volume":"54","author":"IF Walker","year":"2019","journal-title":"Eur Respir J"},{"key":"pmed.1004401.ref079","unstructured":"A concurrent comparison of isoniazid plus PAS with three regimens of isoniazid alone in the domiciliary treatment of pulmonary tuberculosis in South India. Bull World Health Organ. 1960;23:535\u2013585."},{"key":"pmed.1004401.ref080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cmi.2021.08.007","article-title":"Pretomanid for tuberculosis: a systematic review","volume":"28","author":"T Gils","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"pmed.1004401.ref081","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01522-2019","article-title":"Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report","volume":"54","author":"S Borisov","year":"2019","journal-title":"Eur Respir J"},{"key":"pmed.1004401.ref082","doi-asserted-by":"crossref","first-page":"393","DOI":"10.5588\/ijtld.17.0661","article-title":"Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa","volume":"22","author":"K Schnippel","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"pmed.1004401.ref083","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.5588\/ijtld.21.0176","article-title":"Cost of TB services in the public and private sectors in Georgia (No 2)","volume":"25","author":"I Chikovani","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"key":"pmed.1004401.ref084","doi-asserted-by":"crossref","first-page":"228","DOI":"10.5588\/ijtld.20.0586","article-title":"Laboratory costs of diagnosing TB in a high multidrug-resistant TB setting","volume":"25","author":"L Cates","year":"2021","journal-title":"Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis"},{"key":"pmed.1004401.ref085","unstructured":"Myambutol (ethambutol) dosing, indications, interactions, adverse effects, and more. [date accessed: 2023 Feb 18]. Available from: https:\/\/reference.medscape.com\/drug\/myambutol-ethambutol-342677."},{"key":"pmed.1004401.ref086","unstructured":"pyrazinamide: Dosing, contraindications, side effects, and pill pictures \u2010 epocrates online. [date accessed: 2023 Feb 18]. Available from: https:\/\/online.epocrates.com\/drugs\/279\/pyrazinamide."},{"key":"pmed.1004401.ref087","article-title":"Value TB Dataset: costs per intervention","author":"S Sweeney","year":"2021","journal-title":"Harvard Dataverse"},{"key":"pmed.1004401.ref088","unstructured":"UNdata | record view | Life expectancy at birth for both sexes combined (years). [date accessed: 2022 Mar 24]. Available from: http:\/\/data.un.org\/Data.aspx?q=moldova&d=PopDiv&f=variableID:68;crID:498."},{"key":"pmed.1004401.ref089","unstructured":"xe.com Currency Charts. Available from: https:\/\/www.xe.com\/currencycharts\/."},{"key":"pmed.1004401.ref090","unstructured":"World Bank International Comparisons Project. [date accessed: 2022 Mar 21]. Available from: https:\/\/databank.worldbank.org\/embed\/ICP-2017-Cycle\/id\/4add74e?inf=n."},{"key":"pmed.1004401.ref091","doi-asserted-by":"crossref","first-page":"183","DOI":"10.5152\/eurasianjmed.2017.17040","article-title":"Evaluation of the BACTEC MGIT 960 SL DST Kit and the GenoType MTBDRsl Test for Detecting Extensively Drug-resistant Tuberculosis Cases","volume":"49","author":"K Tekin","year":"2017","journal-title":"Eurasian J Med"},{"key":"pmed.1004401.ref092","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/jac\/dkp096","article-title":"Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance","volume":"63","author":"RA Devasia","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"pmed.1004401.ref093","unstructured":"BioSamples from BioProject PRJNA736718. National Center for Biotechnology Information. Available from: https:\/\/www.ncbi.nlm.nih.gov\/biosample?Db=biosample&DbFrom=bioproject&Cmd=Link&LinkName=bioproject_biosample&LinkReadableName=BioSample&ordinalpos=1&IdsFromResult=736718."},{"key":"pmed.1004401.ref094","unstructured":"WHO. Global Tuberculosis Programme: Treatment outcomes. 2023. Available from: https:\/\/extranet.who.int\/tme\/generateCSV.asp?ds=outcomes."}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1004401","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:51:11Z","timestamp":1731891071000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004401"}},"subtitle":[],"editor":[{"given":"Amitabh Bipin","family":"Suthar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":94,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004401","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pmed.1004401","asserted-by":"object"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,3]]}}}